AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05891262
Drug: BMS-986196
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05891262
Drug: Loestrin
RxNorm normalized name: Lo Loestrin Fe
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05667545
Drug: Peptide
RxNorm normalized name: Peptide
DrugBank: ACV tripeptide (DB02025)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: it is about synthetic protein acting on tooth structure help information apatite crystals
Trial: NCT05687448
Drug: Apixaban 5 MG Oral Tablet
RxNorm normalized name: apixaban 5 MG Oral Tablet
DrugBank: Apixaban (DB06605)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients treated with apixaban 5 mg twice daily (BID)
Trial: NCT05687448
Drug: warfarin with an objective of INR target of 2.5 (range: 2.0-3.0)
DrugBank: Warfarin (DB00682)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients treated with warfarin with an objective of INR target of 2.5 (range: 2.0-3.0)
Trial: NCT06408532
Drug: Premixed insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The participants in this group will be have optimized premixed insulin regimen.
Trial: NCT06075849
Drug: PB101
RxNorm normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohorts of 3-6 patients receive PB101 until the MTD is determined. The dose (2 mg/kg-15 mg/kg) assigned to the cohort will be administered weekly for two 28-day cycles or until progressive disease (PD), unacceptable toxicity, withdrawal of subject consent, and/or the investigator's decision to discontinue the study treatment occurs.~Administration may be continued for subjects in whom PB101 provides clinical benefits at the discretion of the investigator.
Trial: NCT04478825
Drug: BBT-401-1S
RxNorm normalized name: MILNACIPRAN, (1S,2R)-
DrugBank: Levomilnacipran (DB08918)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: BBT-401-1S, 8 weeks, once a day
Trial: NCT00002253
Drug: Octreotide
RxNorm normalized name: Octreotide
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05057572
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: - Arm A will receive carvedilol plus standard medical therpy,Carvedilol: will be started with initial dose of 3.125 mg BD then After 3 days, increase the dose to 6.25 mg BD, Maximum dose would be 12.5 mg BD, the same shall be switch to Maximum tollrated dose if SBP\>90, HR \>55.
Trial: NCT05070754
Drug: Canthardin Collodion
RxNorm normalized name: cantharidin
DrugBank: Cantharidin (DB12328)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemical compound that acts as a vesicant to form a blister around treatment area. The blister lifts the lesion of interest away from the skin, causing it to slough off in a few days. It is used as SOC for the treatment of Molluscum Contagiosum.
Trial: NCT04807751
Drug: Delgocitinib cream
RxNorm normalized name: Delgocitinib
DrugBank: Delgocitinib (DB16133)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Cream for topical application
Trial: NCT06449703
Drug: insulin degludec/liraglutide
RxNorm normalized name: INSULIN DEGLUDEC/LIRAGLUTIDE
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the abdomen.
Trial: NCT06469060
Drug: neoadjuvant anti-PD-1 with DOC chemotherapy
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were treated with one cycle of Tislelizumab 200 mg monotherapy on day~1. At 3 weeks and with intervals of 3 weeks between each cycle (weeks 3, 6, 9 and 12), patients received a total of four combination cycles consisting of Tislelizumab 200 mg, docetaxel 50 mg m-2 and oxaliplatin 100 mg m-2 intravenously at the beginning of each cycle, plus oral capecitabine 850 mg m-2 twice daily on days 1-14 of each cycle.
Trial: NCT04807751
Drug: Delgocitinib cream vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Delgocitinib (DB16133)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
Trial: NCT06405464
Drug: VOCABRIA 30Mg Tablet
RxNorm normalized name: VOCABRIA 30mg Tablet
DrugBank: Cabotegravir (DB11751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CAB 30 mg Film-coated tablets
Trial: NCT06405464
Drug: EDURANT 25Mg Tablet
RxNorm normalized name: EDURANT 25mg Tablet
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RPV 25 mg film-coated tablets
Trial: NCT06405464
Drug: Cabotegravir Injectable Suspension
RxNorm normalized name: cabotegravir Injection
DrugBank: Cabotegravir (DB11751)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CAB LA 600 mg prolonged release suspension for injection (3 mL)
Trial: NCT06405464
Drug: Rilpivirine Injectable Suspension
RxNorm normalized name: rilpivirine Injection
DrugBank: Rilpivirine (DB08864)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: RPV LA 900 mg prolonged release suspension for injection (3 mL)
Trial: NCT05642910
Drug: Azvudine
RxNorm normalized name: Azvudine
DrugBank: Azvudine (DB16407)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received Azvudine orally, for 7 consecutive days (7 doses in total)
Trial: NCT04186286
Drug: Ivabradine 4-week course
RxNorm normalized name: milnacipran
DrugBank: Ivabradine (DB09083)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of ivabradine.
Trial: NCT04186286
Drug: Propranolol 4-week course
RxNorm normalized name: milnacipran
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of propranolol.
Trial: NCT04186286
Drug: Placebo 4-week course
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of placebo
Trial: NCT04842435
Drug: COVID-globulin
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In a Stage 1 study, COVID globulin is administered to clinical study subjects randomized to groups 1, 2, or 3 by intravenous drip in one of three doses of 1 mL/kg, 2 mL/kg, or 4 mL/kg The initial drug administration rate is from 0.01 mL/kg to 0.02 mL/kg of body weight per minute for 30 minutes. If the drug is well tolerated, the rate of administration can be gradually increased to a maximum of 0.12 mL/kg of body weight per minute. In order to control the drug administration rate, infusion shall be performed with an infusion pump.~In a Stage 2 study, COVID globulin is administered to clinical study subjects randomized to group 1 by intravenous drip at a dose found optimal based on the results of Stage 1 study.
Trial: NCT04887831
Drug: Trilaciclib
RxNorm normalized name: Trilaciclib
DrugBank: Trilaciclib (DB15442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trilaciclib administered IV prior to chemotherapy and avelumab maintenance therapy on each day chemotherapy and avelumab maintenance therapy is administered.
Trial: NCT04887831
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine administered IV on Day 1 and Day 8 of each 21-day cycle
Trial: NCT04887831
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin administered IV on Day 1 of each 21-day cycle
Trial: NCT04887831
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin administered IV on Day 1 of each 21-day cycle
Trial: NCT04887831
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab will be dosed on Day 1 of each 14-day maintenance cycle
Trial: NCT04787965
Drug: Opicapone
RxNorm normalized name: opicapone
DrugBank: Opicapone (DB11632)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Opicapone as adjunctive treatment to levodopa/carbidopa over a 6-month period
Trial: NCT05432414
Drug: pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide was administered orally at a dose of 4 mg on days 1-14 of each cycle.
Trial: NCT05432414
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib was administered intravenously or subcutaneously at a dose of 1.3mg/m2 on days 1, 4, 8, 11 of each cycle.
Trial: NCT05432414
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone was administered orally at a dose of 20mg on days the same and next day of bortezomib administration.
Trial: NCT06597721
Drug: ADCE-T02
RxNorm normalized name: Adcetris
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered intravenously
Trial: NCT05197231
Drug: IV amino acids
DrugBank: Amino acids (DB09393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV amino acids (Glavamin, Fresenius Kabi) delivered by continuous infusion at a rate of 0.1 g/kg/h. The infusion is started immediately prior to physiotherapy and continued until all blood samples required for outcome assessment are collected during a 90-minute resting period after the exercise session.
Trial: NCT01504282
Drug: mitomycin-C
RxNorm normalized name: Mitomycin-C
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002418
Drug: Emivirine
RxNorm normalized name: Emivirine
DrugBank: Emivirine (DB08188)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002418
Drug: Hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002418
Drug: Nevirapine
RxNorm normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002418
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002418
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05181995
Drug: NYX-783
RxNorm normalized name: NYX-2925
DrugBank: NYX-2925 (DB19149)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NYX-783
Trial: NCT05686993
Drug: Cinnarizine
RxNorm normalized name: cinnarizine
DrugBank: Cinnarizine (DB00568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinnarizine oral 30mg TDS
Trial: NCT05686993
Drug: NIFEdipine ER
RxNorm normalized name: NIFEdipine ER
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine oral 60mg daily extended release
Trial: NCT05068661
Drug: Ropivacaine 0.1% Injectable Solution
RxNorm normalized name: ROPivacaine 0.1% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DPE
Trial: NCT05068661
Drug: Bupivacaine 0.25% Injectable Solution
RxNorm normalized name: BUPivacaine 0.25% injectable solution
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CSE
Trial: NCT06594744
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The initial dosage of carvedilol is set at 6.25 mg daily. In the absence of hypotension (systolic blood pressure \&lt; 90 mmHg), bradycardia (resting heart rate \&lt; 55 beats per minute), or other adverse effects, hospitalized patients may have their dosage increased to 12.5 mg daily after 3 days, while outpatient patients may increase their dosage to 12.5 mg daily after 7 days. This dosage represents the target dose for the trial.
Trial: NCT06597682
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Total 4 weeks of treatment
Trial: NCT06597682
Drug: Budesonide/Formoterol
RxNorm normalized name: BUDESONIDE/FORMOTEROL
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Total 8 weeks of treatment
Trial: NCT06597682
Drug: Montelukast tablets oral treatment
RxNorm normalized name: montelukast Oral Tablet
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Total 8 weeks of treatment
Trial: NCT05510505
Drug: CD20 monoclonal antibody
RxNorm normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4.2 Conditioning Regimen~4.2.1 Matched sibling donor~1. ATG arm (control group) Fludarabine 30mg/m2/d×6d（-7d \~ -2d）+ Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）~2. ATG + CD20 monoclonal antibody (test arm) Fludarabine 30mg/m2/d×6d（-7d \~ -2d） + Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）+ CD20 monoclonal antibody 375mg/m2, -1d~4.2.2 Unrelated donor and haploidentical donor~1. ATG arm (control group) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）~2. ATG + CD20 monoclonal antibody (test arm) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）+ CD20 monoclonal antibody 375mg/m2, -1d
Trial: NCT05510505
Drug: ATG
RxNorm normalized name: eATG
DrugBank: Antilymphocyte immunoglobulin (horse) (DB09312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.2 Conditioning Regimen~4.2.1 Matched sibling donor~1. ATG arm (control group) Fludarabine 30mg/m2/d×6d（-7d \~ -2d）+ Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）~2. ATG + CD20 monoclonal antibody (test arm) Fludarabine 30mg/m2/d×6d（-7d \~ -2d） + Cyclophosphamide 50mg/kg/d×2d （-4d \~ -3d）+ ATG 2.5mg/kg/d×5d（-8d \~ -4d）+ CD20 monoclonal antibody 375mg/m2, -1d~4.2.2 Unrelated donor and haploidentical donor~1. ATG arm (control group) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）~2. ATG + CD20 monoclonal antibody (test arm) Busulfan 3.2 mg/kg/d（0.8 mg/kg，q6h）×2d（-7d \~ -6d） + Cyclophosphamide 50mg/kg/d×4d （-5d \~ -2d）+ ATG 2.5mg/kg/d×4d（-5d \~ -2d）+ CD20 monoclonal antibody 375mg/m2, -1d
Trial: NCT05317806
Drug: Metformin Extended Release Oral Tablet
RxNorm normalized name: metformin Extended Release Oral Tablet
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: daily metformin treatment vs. no treatment with metformin
Trial: NCT05808972
Drug: Sodium chloride 0.9% (SC)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This trial looks specifically at the type of hydratation liquid. The patients included will receive SC. The volume, frequency of fluid administration and other severe DKA therapies, such as insulin therapy and electrolytes, are prescribed similarly. The intervention will continue for 48 hours from admission to the ICU with a blood gas control (including base excess) + Blood glucose + ionogram (Na, K, chlorine) + lactates on admission (or H0), H6, H12, H24 and H48.
Trial: NCT05087615
Drug: Metoclopramide
RxNorm normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This groups only received metoclopramide 0.2 mg/kg IV Bid as antiemetic in the postoperative period.
Trial: NCT05087615
Drug: Ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This groups only received ondansetron 8 mg IV Bid as antiemetic in the postoperative period.
Trial: NCT05087615
Drug: Metoclopramide and Ondanteron
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This groups received both metoclopramide 0.2 mg IV Bid and ondansetron 8 mg IV/Bid as antiemetics in the postoperative period.
Trial: NCT05087615
Drug: Granisetron
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This groups only received granisetron 2 mg IV Bid as antiemetic in the postoperative period.
Trial: NCT06297408
Drug: Relma-cel
RxNorm normalized name: relma-cel
DrugBank: Relmacabtagene autoleucel (DB18979)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19-targeted Chimeric AntigenReceptor (CAR) T Cells
Trial: NCT01418547
Drug: Torrent's Isosorbide Mononitrate 120 mg ER Tablets
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04994431
Drug: Tamsulosin Hydrochloride
RxNorm normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.4mg orally nightly for the two days immediately prior to surgery and the morning of surgery.
Trial: NCT06357741
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Desumumab, 60mg single injection
Trial: NCT04900623
Drug: Chemotherapy drug
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and radiation therapy are both considered standard treatments~* Bolus Cisplatin: Infused every 21 days for up to 2 or 3 doses.~* Weekly Cisplatin or Carboplatin with Paclitaxel: Infused weekly during radiation therapy.
Trial: NCT04771442
Drug: Stromal vascular fraction
RxNorm normalized name: Autologous stromal vascular fraction from adipose tissue
DrugBank: Autologous adipose-derived stromal vascular fraction cells (DB18679)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT05533281
Drug: tropisetron
RxNorm normalized name: tropisetron
DrugBank: Tropisetron (DB11699)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tropisetron was given 30 minutes in advance, and then tramadol 1.5mg/kg was intravenously injected with a micropump at a constant speed.
Trial: NCT05533281
Drug: metoclopramide
RxNorm normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One dose of metoclopramide was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.
Trial: NCT05533281
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of dexamethasone was given 30 minutes in advance, and then tramadol 1.5mg/kg was injected intravenously with a micropump at a constant speed.
Trial: NCT06588595
Drug: Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: After at least 30 days of DAPT \[with aspirin 81-mg qd and a potent P2Y12 inhibitor (prasugrel 10 mg qd or ticagrelor 90-mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients with an ABCD-GENE 10 or more will continue prasugrel 10 mg qd/ticagrelor 90 mg BID and drop aspirin; and patients with an ABCD-GENE less than10 will switch from prasugrel/ticagrelor-based DAPT to aspirin 81 mg qd plus clopidogrel 75 mg qd.
Trial: NCT06628154
Drug: Losartan potassium 50mg
RxNorm normalized name: LOSARTAN POTASSIUM 50MG TAB,UD
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose losartan (50 mg, weight-adjusted), encapsulated identically to placebo
Trial: NCT00002079
Drug: Butyldeoxynojirimycin
RxNorm normalized name: Butyldeoxynojirimycin
DrugBank: Miglustat (DB00419)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00002079
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05550402
Drug: Salbutamol
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Visit 1, After predosed spirometry is done, the patients will be received 4 puffs of salbutamol. 30 minutes later, if they meet the criteria of fixed airway obstruction based on ATS criteria, then they will continue to undergo serial spirometry at 1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of ipratropium and do spirometry at 4.5 and 5 hours.
Trial: NCT05550402
Drug: Ipratropium Bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Visit 2, After predosed spirometry is done, the patients will be received 4 puffs of ipratropium they will continue to undergo serial spirometry at 30 minutes,1, 2, 3, and 4 hours. Then, the patients requested to be administered 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours.
Trial: NCT05550402
Drug: Salbutamol plus Ipratropium Bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Visit 3, After predosed spirometry is done, the patients will be received 4 puffs of a placebo, and they will do spirometry at 30 minutes, 1 and 2 hours (Placebo arm). Then, the patients requested to be administered 4 puffs of ipratropium and 4 puffs of salbutamol and do spirometry at 4.5 and 5 hours (Salbutamol plus ipratropium arm)
Trial: NCT05252117
Drug: Articaine Hydrochloride 40 MG/ML
RxNorm normalized name: articaine hydrochloride 40 MG/ML
DrugBank: Articaine (DB09009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Analysis of uterovaginal plexus block with articain for intrauterine device placement
Trial: NCT05252117
Drug: Mepivacaine
RxNorm normalized name: Mepivacaine
DrugBank: Mepivacaine (DB00961)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Analysis of uterovaginal plexus block with mepivacaine for intrauterine device placement